Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection

Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus

Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z., Qiu, H., Xu, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304459 · Cited by 2,310

Antibody Recognition of a Highly Conserved Influenza Virus Epitope

Ekiert, D. C., Bhabha, G., Elsliger, M.-A., Friesen, R. H. E., Jongeneelen, M., Throsby, M., Goudsmit, J., & Wilson, I. A. (2009) · Science · doi:10.1126/science.1171491 · Cited by 1,326

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K. E., Larsen, C. P., Zheng, N., Mays, I., Garman, L., Helms, C., et al. (2008) · Nature · doi:10.1038/nature06890 · Cited by 1,026

Highly Conserved Protective Epitopes on Influenza B Viruses

Dreyfus, C., Laursen, N. S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D. C., Lee, J. H., Metlagel, Z., Bujny, M. V., Jongeneelen, M. A. C., et al. (2012) · Science · doi:10.1126/science.1222908 · Cited by 857

A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses

Ekiert, D. C., Friesen, R. H. E., Bhabha, G., Kwaks, T., Jongeneelen, M. A. C., Yu, W., Ophorst, C., Cox, F., Korse, H. J. W. M., Brandenburg, B., et al. (2011) · Science · doi:10.1126/science.1204839 · Cited by 820

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

Wrammert, J., Koutsonanos, D., Li, G., Edupuganti, S., Sui, J., Michael, M., McCausland, M. M., Skountzou, I., Hornig, M., Lipkin, W. I., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101352 · Cited by 777

Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

DiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749

Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine

Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., & Wolff, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055778 · Cited by 698

Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study

Chen, H., Yuan, H., Gao, R., Zhang, J., Wang, D., Xiong, Y., Fan, G., Yang, F., Li, X., Zhou, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60111-2 · Cited by 648

Advances in the development of influenza virus vaccines

Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 592

The human antibody response to influenza A virus infection and vaccination

Krammer, F. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0143-6 · Cited by 819

Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans

Hagan, T., Cortese, M., Rouphael, N., Boudreau, C., Linde, C., Maddur, M. S., Das, J., Wang, H., Guthmiller, J., Zheng, N.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.010 · Cited by 572

Natural polyreactive IgA antibodies coat the intestinal microbiota

Bunker, J. J., Erickson, S. A., Flynn, T. M., Henry, C., Koval, J., Meisel, M., Jabrì, B., Antonopoulos, D. A., Wilson, P. C., & Bendelac, A. S. (2017) · Science · doi:10.1126/science.aan6619 · Cited by 470

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460

Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies

Chen, Y.-Q., Wohlbold, T. J., Zheng, N., Huang, M., Huang, Y., Neu, K. E., Lee, J., Wan, H., Rojas, K. T., Roubidoux, E. K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.030 · Cited by 419

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281

Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease

van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 291

Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination

Lee, J., Boutz, D. R., Chromikova, V., Joyce, M. G., Vollmers, C., Leung, K., Horton, A. P., DeKosky, B. J., Lee, C., Lavinder, J. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.4224 · Cited by 278

From Original Antigenic Sin to the Universal Influenza Virus Vaccine

Henry, C., Palm, A.-K. E., Krammer, F., & Wilson, P. C. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.08.003 · Cited by 262

Influenza Hemagglutinin Structures and Antibody RecognitionPreprint

Wu, N. C., & Wilson, I. A. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038778 · Cited by 253

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2Preprint

Cathcart, A. L., Havenar‐Daughton, C., Lempp, F. A., Ma, D., Schmid, M., Agostini, M. L., Guarino, B., di Iulio, J., Rosen, L. E., Tucker, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.09.434607 · Cited by 210

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection

Saphire, E. O., Schendel, S. L., Fusco, M. L., Gangavarapu, K., Gunn, B. M., Wec, A. Z., Halfmann, P. J., Brannan, J. M., Herbert, A. S., Qiu, X., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.033 · Cited by 212

Original Antigenic Sin: How First Exposure Shapes Lifelong Anti–Influenza Virus Immune Responses

Zhang, A., Stacey, H. D., Mullarkey, C. E., & Miller, M. S. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801149 · Cited by 195

Universal influenza virus vaccines and therapeutic antibodies

Nachbagauer, R., & Krammer, F. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.02.009 · Cited by 184

Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus

He, W., Tan, G. S., Mullarkey, C. E., Lee, A. J., Lam, M. M. W., Krammer, F., Henry, C., Wilson, P. C., Ashkar, A. A., Palese, P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609316113 · Cited by 180

Systems serology detects functionally distinct coronavirus antibody features in children and elderly

Selva, K. J., van de Sandt, C. E., Lemke, M. M., Lee, C. Y., Shoffner, S. K., Chua, B. Y. L., Davis, S. K., Nguyen, T. H. O., Rowntree, L. C., Hensen, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22236-7 · Cited by 179

Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins

Nachbagauer, R., Choi, A., Hirsh, A., Margine, I., Iida, S., Barrera, A., Marcela Ferrés, G., Albrecht, R. A., García‐Sastre, A., Bouvier, N. M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3684 · Cited by 172

Defining the risk of SARS-CoV-2 variants on immune protection

DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04690-5 · Cited by 168

Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice

He, W., Chen, C.-J., Mullarkey, C. E., Hamilton, J. R., Wong, C. K., Leon, P. E., Uccellini, M. B., Chromikova, V., Henry, C., Hoffman, K. W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00928-3 · Cited by 168

A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination

Junkins, R. D., Gallovic, M. D., Johnson, B. M., Collier, M. A., Watkins-Schulz, R., Cheng, N., David, C. N., McGee, C. E., Sempowski, G. D., Shterev, I. D., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.030 · Cited by 144

SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase

Srivastava, K., Carreño, J. M., Gleason, C., Monahan, B., Singh, G., Abbad, A., Tcheou, J., Raskin, A. J., Kleiner, G., van Bakel, H., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.017 · Cited by 162

Antibody-mediated protection against Ebola virus

Saphire, E. O., Schendel, S. L., Gunn, B. M., Milligan, J. C., & Alter, G. (2018) · Nature Immunology · doi:10.1038/s41590-018-0233-9 · Cited by 136

Aging and influenza vaccine-induced immunity

Dugan, H. L., Henry, C., & Wilson, P. C. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103998 · Cited by 137

Tackling influenza with broadly neutralizing antibodies

Corti, D., Cameroni, E., Guarino, B., Kallewaard, N. L., Zhu, Q., & Lanzavecchia, A. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.03.002 · Cited by 133

Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes

Wohlbold, T. J., Podolsky, K. A., Chromikova, V., Roubidoux, E. K., Falconieri, V., Meade, P. S., Amanat, F., Tan, J., tenOever, B. R., Tan, G. S., et al. (2017) · Nature Microbiology · doi:10.1038/s41564-017-0011-8 · Cited by 130

Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact

Leon, P. E., He, W., Mullarkey, C. E., Bailey, M. J., Miller, M. S., Krammer, F., Palese, P., & Tan, G. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613225113 · Cited by 118

Preferential induction of cross-group influenza A hemagglutinin stem–specific memory B cells after H7N9 immunization in humans

Andrews, S. F., Joyce, M. G., Chambers, M. J., Gillespie, R. A., Kanekiyo, M., Leung, K., Yang, E. S., Tsybovsky, Y., Wheatley, A. K., Crank, M. C., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan2676 · Cited by 116

Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model

Bailey, M. J., Duehr, J. E., Dulin, H., Broecker, F., Brown, J. A., Arumemi, F., González, M. C. B., Leyva-Grado, V. H., Evans, M. J., Simon, V. R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07008-0 · Cited by 104

Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination

Lindesmith, L. C., McDaniel, J. R., Changela, A., Verardi, R., Kerr, S. A., Costantini, V., Brewer-Jensen, P. D., Mallory, M. L., Voss, W. N., Boutz, D. R., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.05.007 · Cited by 104

Designing a multi-epitope vaccine to provoke the robust immune response against influenza A H7N9

Tarrahimofrad, H., Rahimnahal, S., Zamani, J., Jahangirian, E., & Aminzadeh, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-03932-2 · Cited by 107

Immunosensor-based label-free and multiplex detection of influenza viruses: State of the art

Zhang, H., & Miller, B. L. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111476 · Cited by 100

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma

Natarajan, H., Crowley, A. R., Butler, S. E., Xu, S., Weiner, J. A., Bloch, E. M., Littlefield, K. E., Wieland‐Alter, W., Connor, R. I., Wright, P. F., et al. (2021) · mBio · doi:10.1128/mbio.00765-21 · Cited by 99

Is It Possible to Develop a “Universal” Influenza Virus Vaccine?Preprint

Krammer, F., García‐Sastre, A., & Palese, P. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028845 · Cited by 96

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus

Bootz, A., Karbach, A., Spindler, J., Kropff, B., Reuter, N., Sticht, H., Winkler, T., Britt, W. J., & Mach, M. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006601 · Cited by 95

Polyreactive Broadly Neutralizing B Cells are Selected to Provide Defense Against Pandemic Threat Influenza Viruses

Guthmiller, J. J., Lan, L. Y.-L., Fernández‐Quintero, M. L., Han, J., Utset, H. A., Bitar, D. J., Hamel, N. J., Stovicek, O., Li, L., Tepora, M. E., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.005 · Cited by 93

SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 90

Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies

Dufloo, J., Grzelak, L., Staropoli, I., Madec, Y., Tondeur, L., Anna, F., Pelleau, S., Wiedemann, A., Planchais, C., Buchrieser, J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100275 · Cited by 89

Influenza Neuraminidase Characteristics and Potential as a Vaccine Target

Creytens, S., Pascha, M. N., Ballegeer, M., Saelens, X., & de Haan, C. A. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786617 · Cited by 88

Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?

Neu, K. E., Henry, C., & Wilson, P. C. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.012 · Cited by 87

Influenza and Antibody-Dependent Cellular Cytotoxicity

Holle, T. A. V., & Moody, M. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01457 · Cited by 83

Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

Batty, C. J., Heise, M. T., Bachelder, E. M., & Ainslie, K. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.006 · Cited by 86

Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice

Asthagiri Arunkumar, G., Ioannou, A., Wohlbold, T. J., Meade, P., Aslam, S., Amanat, F., Ayllon, J., García-Sastre, A., & Krammer, F. (2019) · Journal of Virology · doi:10.1128/jvi.01696-18 · Cited by 80

Modulating Antibody Functionality in Infectious Disease and Vaccination

Gunn, B. M., & Alter, G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.09.002 · Cited by 82

First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes

Guthmiller, J. J., Han, J., Li, L., Freyn, A. W., Liu, S. T. H., Stovicek, O., Stamper, C. T., Dugan, H. L., Tepora, M. E., Utset, H. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg4535 · Cited by 77

Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies

Ilinykh, P. A., Huang, K., Santos, R. I., Gilchuk, P., Gunn, B. M., Karim, M. M., Liang, J. Y.-J., Fouch, M. E., Davidson, E., Parekh, D. V., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.025 · Cited by 75

Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model

Jacobsen, H., Rajendran, M., Choi, A., Sjursen, H., Brokstad, K. A., Cox, R. J., Palese, P., Krammer, F., & Nachbagauer, R. (2017) · mBio · doi:10.1128/mbio.01463-17 · Cited by 73

Clinical and Immunological Characteristics of Human Infections With H5N6 Avian Influenza Virus

Bi, Y., Tan, S., Yang, Y., Wong, G., Zhao, M. J., Zhang, Q., Wang, Q., Zhao, X., Li, L., Yuan, J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy681 · Cited by 73

Protective mechanisms of nonneutralizing antiviral antibodies

Chandler, T. L., Yang, A., Otero, C. E., Permar, S. R., & Caddy, S. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011670 · Cited by 69

Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance

Chen, Y.-Q., Lan, L. Y.-L., Huang, M., Henry, C., & Wilson, P. C. (2018) · Journal of Virology · doi:10.1128/jvi.01526-18 · Cited by 69

Refined protocol for generating monoclonal antibodies from single human and murine B cells

Ho, I. Y., Bunker, J. J., Erickson, S. A., Neu, K. E., Huang, M., Cortese, M., Pulendran, B., & Wilson, P. C. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.09.001 · Cited by 68

Influenza Virus Infection Induces a Narrow Antibody Response in Children but a Broad Recall Response in Adults

Meade, P. S., Kuan, G. M., Strohmeier, S., Maier, H. E., Amanat, F., Balmaseda, Á., Ito, K., Roubidoux, E. K., Javier, A., Gresh, L., et al. (2020) · mBio · doi:10.1128/mbio.03243-19 · Cited by 67

Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens

Coughlan, L., Kremer, E. J., & Shayakhmetov, D. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.034 · Cited by 67

Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients

Carreño, J. M., Alshammary, H., Singh, G., Raskin, A. J., Amanat, F., Amoako, A. A., Gonzalez-Reiche, A. S., van de Guchte, A., PARIS study group, Awawda, M. H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103626 · Cited by 61

Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection

de Vries, R. D., Nieuwkoop, N. J., Pronk, M., de Bruin, E., Leroux-Roels, G., Huijskens, E. G. W., van Binnendijk, R. S., Krammer, F., Koopmans, M. P. G., & Rimmelzwaan, G. F. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.11.082 · Cited by 63

Natural and directed antigenic drift of the H1 influenza virus hemagglutinin stalk domain

Anderson, C., Ortega, S., Chaves, F. A., Knudsen-Clark, A. M., Yang, H., Topham, D. J., & DeDiego, M. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-14931-7 · Cited by 62

GII.4 Human Norovirus: Surveying the Antigenic Landscape

Mallory, M. L., Lindesmith, L. C., Graham, R. L., & Baric, R. S. (2019) · Viruses · doi:10.3390/v11020177 · Cited by 62

The re-emergence of highly pathogenic avian influenza H7N9 viruses in humans in mainland China, 2019

Yu, D., Xiang, G., Zhu, W., Lei, X., Li, B., Meng, Y., Yang, L., Jiao, H., Li, X., Huang, W., et al. (2019) · Eurosurveillance · doi:10.2807/1560-7917.es.2019.24.21.1900273 · Cited by 61

Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses

Moin, S. M., Boyington, J. C., Boyoglu-Barnum, S., Gillespie, R. A., Cerutti, G., Cheung, C. S., Cagigi, A., Gallagher, J. R., Brand, J., Prabhakaran, M. S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.015 · Cited by 61

Harnessing immune history to combat influenza viruses

Guthmiller, J. J., & Wilson, P. C. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.05.010 · Cited by 61

A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin

Yu, F., He, S., Wu, Y., Chang, S. Y., Wang, L., Li, W., Hong, B., Xia, S., Wang, C., Khurana, S., et al. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.08.011 · Cited by 60

The protective potential of Fc‐mediated antibody functions against influenza virus and other viral pathogens

Vanderven, H. A., & Kent, S. J. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12312 · Cited by 59

Immune Control of Avian Influenza Virus Infection and Its Vaccine Development

Dey, P., Ahuja, A., Panwar, J., Choudhary, P., Rani, S., Kaur, M., Sharma, A., Kaur, J. K., Yadav, A. K., Sood, V., et al. (2023) · Vaccines · doi:10.3390/vaccines11030593 · Cited by 65

Human seasonal influenza A viruses induce H7N9-cross-reactive antibody-dependent cellular cytotoxicity (ADCC) antibodies that are directed towards the nucleoprotein

Jegaskanda, S., Co, M. D. T., Cruz, J., Subbarao, K., Ennis, F. A., & Terajima, M. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw629 · Cited by 58

HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids

Cox, F., Kwaks, T., Brandenburg, B., Koldijk, M. H., Klaren, V., Smal, B., Korse, H. J. W. M., Geelen, E., Tettero, L., Zuijdgeest, D., et al. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00399 · Cited by 57

Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic

Liu, W. J., Xiao, H., Dai, L., Liu, D., Chen, J., Qi, X., Bi, Y., Shi, Y., Gao, G. F., & Liu, Y. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0814-5 · Cited by 53

Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies

Nakajima, R., Supnet, M., Jasinskas, A., Jain, A., Taghavian, O., Obiero, J. M., Milton, D. K., Chen, W. H., Grantham, M. L., Webby, R. J., et al. (2018) · mSphere · doi:10.1128/msphere.00592-18 · Cited by 52

Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model

Park, J.-K., Xiao, Y., Ramuta, M. D., Rosas, L. A., Fong, S. E., Matthews, L., Freeman, A. D., Gouzoulis, M. A., Batchenkova, N. A., Yang, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0937-x · Cited by 52

B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat

Guthmiller, J. J., Utset, H. A., & Wilson, P. C. (2021) · Viruses · doi:10.3390/v13060965 · Cited by 56

One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines

Ilchmann, H., Samy, N., Reichhardt, D., Schmidt, D., Powell, J. D., Meyer, T. P. H., Silbernagl, G., Nichols, R., Weidenthaler, H., Moerlooze, L. D., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac455 · Cited by 51

Fc functional antibodies in humans with severe H7N9 and seasonal influenza

Vanderven, H. A., Liu, L., Ana‐Sosa‐Batiz, F., Nguyen, T. H. O., Wan, Y., Wines, B. D., Hogarth, P. M., Tilmanis, D., Reynaldi, A., Parsons, M. S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92750 · Cited by 51

Structure–function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans

Huang, K.-Y. A., Rijal, P., Jiang, H., Wang, B., Schimanski, L. M., Dong, T., Liu, Y.-M., Chang, P., Iqbal, M., Wang, M.-C., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0303-7 · Cited by 50

An Efficient Method to Generate Monoclonal Antibodies from Human B Cells

Guthmiller, J. J., Dugan, H. L., Neu, K. E., Lan, L. Y.-L., & Wilson, P. C. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_5 · Cited by 50

Epitopes in the HA and NA of H5 and H7 avian influenza viruses that are important for antigenic drift

Luczo, J. M., & Spackman, E. (2024) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuae014 · Cited by 49

Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function

Gao, R., Sheng, Z., Sreenivasan, C. C., Wang, D., & Li, F. (2020) · Viruses · doi:10.3390/v12030276 · Cited by 47

Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses

Amanat, F., Duehr, J. E., Oestereich, L., Hastie, K. M., Saphire, E. O., & Krammer, F. (2018) · mSphere · doi:10.1128/msphere.00189-18 · Cited by 48

Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways

Jegaskanda, S., Vanderven, H. A., Tan, H., Alcântara, S., Wragg, K. M., Parsons, M. S., Chung, A. W., Juno, J. A., & Kent, S. J. (2018) · Journal of Virology · doi:10.1128/jvi.02090-18 · Cited by 51

Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design

Jegaskanda, S., Vanderven, H. A., Wheatley, A. K., & Kent, S. J. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1290018 · Cited by 48

Effector mechanisms of influenza-specific antibodies: neutralization and beyond

Sicca, F., Neppelenbroek, S., & Huckriede, A. L. W. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1516553 · Cited by 47

Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains

Turner, H. L., Pallesen, J., Lang, S., Bangaru, S., Urata, S. M., Li, S., Cottrell, C. A., Bowman, C. A., Crowe, J. E., Wilson, I. A., et al. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000139 · Cited by 47

Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination

Clark, J. J., Hoxie, I., Adelsberg, D. C., Sapse, I. A., Andreata‐Santos, R., Yong, J. S., Amanat, F., Tcheou, J., Raskin, A. J., Singh, G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114922 · Cited by 43

Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo

DiPiazza, A. T., Nogales, A., Poulton, N. C., Wilson, P. C., Martínez‐Sobrido, L., & Sant, A. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-11313-x · Cited by 43

Fatty Acid Metabolism is Associated With Disease Severity After H7N9 Infection

Sun, X., Song, L., Feng, S., Li, L., Yu, H., Wang, Q., Wang, X., Hou, Z., Li, X., Li, Y., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.06.019 · Cited by 43

Newcastle disease virus (NDV) recombinant expressing the hemagglutinin of H7N9 avian influenza virus protects chickens against NDV and highly pathogenic avian influenza A (H7N9) virus challenges

Hu, Z., Liu, X., Jiao, X., & Liu, X. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.10.010 · Cited by 42

Non-neutralizing Antibodies Directed at Conservative Influenza Antigens

Sedova, E. S., Щербинин, Д. Н., Lysenko, A. A., Alekseeva, S. V., Artemova, E. A., & Шмаров, М. М. (2019) · Acta Naturae · doi:10.32607/20758251-2019-11-4-22-32 · Cited by 44

Strategies to induce broadly protective antibody responses to viral glycoproteins

Krammer, F. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1299576 · Cited by 41

Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans

Stadlbauer, D., Rajabhathor, A., Amanat, F., Kaplan, D., Masud, A., Treanor, J. J., Izikson, R., Cox, M. M. J., Nachbagauer, R., & Krammer, F. (2017) · mSphere · doi:10.1128/msphere.00502-17 · Cited by 41

Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies

Adachi, Y., Tonouchi, K., Nithichanon, A., Kuraoka, M., Watanabe, A., Shinnakasu, R., Asanuma, H., Ainai, A., Ohmi, Y., Yamamoto, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11821-6 · Cited by 41

Antibody-Dependent Cellular Cytotoxicity Responses to Seasonal Influenza Vaccination in Older Adults

Vanderven, H. A., Jegaskanda, S., Wines, B. D., Hogarth, P. M., Carmuglia, S., Rockman, S. P., Chung, A. W., & Kent, S. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix554 · Cited by 40

Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus

Jin, J., & Simmons, G. (2019) · Viruses · doi:10.3390/v11040305 · Cited by 40

A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice

Bliss, C. M., Freyn, A. W., Caniels, T. G., Leyva-Grado, V. H., Nachbagauer, R., Sun, W., Tan, G. S., Gillespie, V., McMahon, M., Krammer, F., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.011 · Cited by 40

Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk–Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity

de Vries, R. D., Nieuwkoop, N. J., van der Klis, F. R. M., Koopmans, M. P. G., Krammer, F., & Rimmelzwaan, G. F. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix546 · Cited by 39

Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response

Zolla‐Pazner, S., Powell, R. L. R., Yahyaei, S., Williams, C. A. U., Jiang, X., Li, W., Lu, S., Wang, S., Upadhyay, C., Hioe, C. E., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01403-16 · Cited by 39

Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge

Nachbagauer, R., Shore, D. A., Yang, H., Johnson, S. K., Gabbard, J. D., Tompkins, S. M., Wrammert, J., Wilson, P. C., Stevens, J., Ahmed, R., et al. (2018) · Journal of Virology · doi:10.1128/jvi.00949-18 · Cited by 38

Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections

Keeler, S. P., & Fox, J. M. (2021) · Viruses · doi:10.3390/v13061037 · Cited by 38

The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza Strains

Nienen, M., Stervbo, U., Mölder, F., Kaliszczyk, S., Kuchenbecker, L., Gayova, L., Schweiger, B., Jürchott, K., Hecht, J., Neumann, A. U., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00593 · Cited by 36

The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza

Smith, A. M., & Huber, V. C. (2017) · Viral Immunology · doi:10.1089/vim.2017.0138 · Cited by 36

Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo

Epstein, S. L. (2018) · American Journal of Epidemiology · doi:10.1093/aje/kwy145 · Cited by 36

Maternal gatekeepers: How maternal antibody Fc characteristics influence passive transfer and infant protection

Langel, S. N., Otero, C. E., Martinez, D. R., & Permar, S. R. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008303 · Cited by 35

Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans

Liu, L., Nachbagauer, R., Zhu, L., Huang, Y., Xie, X., Jin, S., Zhang, A., Wan, Y., Hirsh, A., Tian, D., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw608 · Cited by 34

A Gene Constellation in Avian Influenza A (H7N9) Viruses May Have Facilitated the Fifth Wave Outbreak in China

Zhu, W., Dong, J., Zhang, Y., Yang, L., Li, X., Chen, T., Zhao, X., Wei, H., Bo, H., Zeng, X., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.081 · Cited by 34

Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection

Tan, G. S., Leon, P. E., Albrecht, R. A., Margine, I., Hirsh, A., Bahl, J., & Krammer, F. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005578 · Cited by 147

An H7N1 Influenza Virus Vaccine Induces Broadly Reactive Antibody Responses against H7N9 in Humans

Krammer, F., Jul‐Larsen, Å., Margine, I., Hirsh, A., Sjursen, H., Zambon, M. C. F. A., & Cox, R. J. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00272-14 · Cited by 52

RESEARCH ARTICLE Antibodies to Antigenic Site A of Influenza H7 Hemagglutinin Provide Protection against H7N9 Challenge

Schmeisser, F., Vasudevan, A., Verma, S., Wang, W., Alvarado-Facundo, E., Weiss, C. D., Atukorale, V. N., Meseda, C. A., & Weir, J. P. (2016)

Antibodies to Antigenic Site A of Influenza H7 Hemagglutinin Provide Protection against H7N9 Challenge

Schmeisser, F., Vasudevan, A., Verma, S., Wang, W., Alvarado-Facundo, E., Weiss, C. D., Atukorale, V. N., Meseda, C. A., & Weir, J. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117108 · Cited by 35

Preexisting human antibodies neutralize recently emerged H7N9 influenza strains

Henry, C., Leon, P. E., Kaur, K., Tan, G. S., Zheng, N., Andrews, S., Huang, M., Qu, X., Huang, Y., Ferrer, M. S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74374 · Cited by 127